Physician profile
Mitchell L Earley
NPI 1235179003
$1,278.49
in general payments reported to CMS, 2019-2025
20 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2022: $42.76 · 2023: $94.63 · 2024: $246 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $364.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $243.52 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $144.03 | 2019-2025 | Vraylar |
| Amgen INC. | $83.15 | 2019-2025 | Otezla, Repatha |
| Astellas Pharma US INC | $70.28 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.56 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $43.04 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $31.39 | 2019-2025 | Farxiga |
| Pfizer INC. | $30.01 | 2019-2025 | |
| Abbott Laboratories | $25.28 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $25.27 | 2025 | Jardiance |
| Corcept Therapeutics | $24.26 | 2025 | Korlym |
| Medtronic, INC. | $23.48 | 2025 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $22.10 | 2025 | Inspire |
| Aytu Biopharma, INC. | $22.04 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.87 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.83 | 2022 | |
| Merck Sharp & Dohme LLC | $14.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.58 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Earley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.